ObjectiveTo evaluate antihypertensive efficacy and safety of different zilebesiran dosing regimens. Design, Setting, and ParticipantsThis phase 2, randomized, double-blind, dose-ranging study of zilebesiran vs placebo was performed at 78 sites across 4 countries. Screening initiation occurred in July ...
CONSISTENT ANTIHYPERTENSIVE EFFICACY OF THE RNA INTERFERENCE THERAPEUTIC ZILEBESIRAN: SUBGROUP RESULTS FROM THE KARDIA-1 PHASE 2 STUDY IN PATIENTS WITH HYPERTENSION Author links open overlay panelMANISH SAXENA, Akshay S. Desai, Michel Azizi, Anil Gupta, Jongtae Lee, Daniel Stiglitz, Nune Makarova, ...
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk Nov 11, 2023 –Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Pl...
CONSISTENT ANTIHYPERTENSIVE EFFICACY OF THE RNA INTERFERENCE THERAPEUTIC ZILEBESIRAN: SUBGROUP RESULTS FROM THE KARDIA-1 PHASE 2 STUDY IN PATIENTS WITH HYPERTENSION 来自 科研支点 喜欢 0 阅读量: 3 作者:M Saxena,AS Desai,M Azizi,A Gupta,J Lee,D Stiglitz,N Makarova,N Goyal,W Guo,D Zappe ...
Offers results of a study, the objective of which was to develop clinical, demographic and pathological profiles of young competitive athletes who died sud... Maron,Barry,J.,... - 《Jama Journal of the American Medical Association》 被引量: 1488发表: 1996年 Causes of sudden death in competi...